MCID: OPT003
MIFTS: 49

Opiate Dependence

Categories: Mental diseases

Aliases & Classifications for Opiate Dependence

MalaCards integrated aliases for Opiate Dependence:

Name: Opiate Dependence 12 15
Opioid Dependence 74 54 17
Opioid-Related Disorders 71
Opioid Type Dependence 12
Opiate Addiction 71

Classifications:



External Ids:

Disease Ontology 12 DOID:2559
ICD9CM 34 304.00
MeSH 44 D009293
SNOMED-CT 67 75544000
ICD10 32 F11.2
UMLS 71 C0027412 C0524662

Summaries for Opiate Dependence

Disease Ontology : 12 A drug dependence that involves the continued use of opiate drugs despite despite problems related to use of the substance.

MalaCards based summary : Opiate Dependence, also known as opioid dependence, is related to opioid dependence 1 and opioid addiction. An important gene associated with Opiate Dependence is ODS1 (Opioid Dependence, Susceptibility To, 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Guaifenesin and Lofexidine have been mentioned in the context of this disorder. Affiliated tissues include brain, amygdala and bone, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 74 Opioid use disorder (OUD) is a substance use disorder relating to the use of an opioid. Any such... more...

Related Diseases for Opiate Dependence

Diseases related to Opiate Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 192)
# Related Disease Score Top Affiliating Genes
1 opioid dependence 1 32.8 OPRM1 ODS1
2 opioid addiction 31.9 OPRM1 OPRK1 OPRD1 DRD2
3 morphine dependence 31.4 PDYN OPRM1 OPRK1 OPRD1 FOS CREB1
4 heroin dependence 31.4 SLC6A4 PDYN OPRM1 OPRD1 DRD2 ANKK1
5 sexual disorder 30.7 VEGFA SLC6A4 POMC IGF1
6 cocaine abuse 30.3 SLC6A4 OPRK1 NGF DRD2
7 phobic disorder 30.2 SLC6A4 POMC DRD2
8 mental depression 30.2 TPH1 SLC6A4 POMC DRD2 CREB1
9 schizoaffective disorder 30.1 SLC6A4 DRD3 DRD2
10 post-traumatic stress disorder 30.1 SLC6A4 POMC DRD2
11 panic disorder 30.1 TPH1 SLC6A4 POMC DRD3 DRD2
12 neonatal abstinence syndrome 30.1 PDYN OPRM1 OPRK1 OPRD1
13 borderline personality disorder 30.1 TPH1 SLC6A4 DRD2
14 conduct disorder 30.1 TPH1 SLC6A4 POMC DRD2
15 sudden infant death syndrome 30.0 VEGFA TPH1 TH SLC6A4
16 opioid abuse 30.0 POMC PDYN OPRM1 OPRK1 OPRD1 NPFF
17 constipation 30.0 TH SLC6A4 PDYN OPRM1 LOC110806262
18 personality disorder 30.0 TPH1 TH SLC6A4 DRD3 DRD2 ANKK1
19 obsessive-compulsive personality disorder 30.0 SLC6A4 DRD3
20 withdrawal disorder 30.0 POMC PDYN OPRM1 OPRK1 NPFF FOS
21 somatoform disorder 29.9 TPH1 SLC6A4 OPRM1 NGF LOC110806262
22 antisocial personality disorder 29.9 SLC6A4 LOC110806262 DRD2 ANKK1
23 substance abuse 29.9 SLC6A4 POMC PDYN OPRM1 DRD3 DRD2
24 restless legs syndrome 29.9 TH SLC6A4 POMC DRD3 DRD2
25 alcohol use disorder 29.8 SLC6A4 OPRM1 LOC110806262 DRD3 DRD2 CREB1
26 drug dependence 29.7 SLC6A4 POMC PDYN OPRM1 OPRK1 OPRD1
27 mood disorder 29.7 TPH1 TH SLC6A4 POMC DRD3 DRD2
28 major depressive disorder 29.7 TPH1 SLC6A4 POMC OPRM1 NGF DRD3
29 anxiety 29.6 TPH1 TH SLC6A4 POMC PDYN OPRM1
30 sleep disorder 29.5 TH SLC6A4 POMC PDYN IGF1 FOS
31 tobacco addiction 29.5 TPH1 SLC6A4 PDYN OPRM1 DRD3 DRD2
32 bipolar disorder 29.2 TPH1 TH SLC6A4 PDYN NGF IGF1
33 cocaine dependence 29.2 SLC6A4 POMC PDYN OPRM1 OPRK1 OPRD1
34 pain agnosia 29.1 POMC PDYN OPRM1 OPRK1 OPRD1 NPFF
35 substance dependence 29.1 TPH1 SLC6A4 POMC PDYN OPRM1 OPRK1
36 alcohol dependence 28.9 TPH1 TH SLC6A4 POMC PDYN OPRM1
37 attention deficit-hyperactivity disorder 28.9 TPH1 TH SLC6A4 OPRM1 NGF FOS
38 schizophrenia 28.6 TPH1 TH SLC6A4 POMC PDYN OPRM1
39 wissler-fanconi syndrome 10.4 TPH1 POMC
40 functionless pituitary adenoma 10.4 POMC IGF1
41 acidophil adenoma 10.4 POMC IGF1
42 myofascial pain syndrome 10.3 POMC NGF
43 adjustment disorder 10.3 TH SLC6A4 POMC
44 neurotic disorder 10.3 SLC6A4 POMC NGF
45 barbiturate abuse 10.3 POMC OPRM1
46 pituitary infarct 10.3 POMC IGF1
47 somatization disorder 10.3 SLC6A4 POMC
48 diabetic encephalopathy 10.3 NGF IGF1 CREB1
49 melancholia 10.3 SLC6A4 POMC LOC110806262
50 prolactin producing pituitary tumor 10.3 POMC DRD2

Graphical network of the top 20 diseases related to Opiate Dependence:



Diseases related to Opiate Dependence

Symptoms & Phenotypes for Opiate Dependence

MGI Mouse Phenotypes related to Opiate Dependence:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.33 CREB1 DRD2 DRD3 FOS NGF NPFF
2 homeostasis/metabolism MP:0005376 10.22 CREB1 DRD2 DRD3 FOS IGF1 NGF
3 growth/size/body region MP:0005378 10.18 CREB1 DRD2 DRD3 FOS IGF1 NGF
4 cardiovascular system MP:0005385 10.17 CREB1 DRD2 DRD3 FOS IGF1 NGF
5 endocrine/exocrine gland MP:0005379 10.14 CREB1 DRD2 FOS IGF1 OPRK1 OPRM1
6 adipose tissue MP:0005375 10.08 DRD2 DRD3 FOS IGF1 OPRM1 PDYN
7 integument MP:0010771 10.07 DRD2 FOS IGF1 NGF OPRD1 OPRK1
8 nervous system MP:0003631 10 CREB1 DRD2 DRD3 FOS IGF1 NGF
9 no phenotypic analysis MP:0003012 9.56 DRD2 NGF OPRD1 OPRM1 PDYN POMC
10 normal MP:0002873 9.32 CREB1 DRD2 FOS IGF1 KPNA3 NGF

Drugs & Therapeutics for Opiate Dependence

Drugs for Opiate Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 286)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
2
Lofexidine Approved, Investigational Phase 4 31036-80-3 30668
3
Clonidine Approved Phase 4 4205-90-7 2803
4
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
5
Ribavirin Approved Phase 4 36791-04-5 37542
6
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
7
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
8
Norepinephrine Approved Phase 4 51-41-2 439260
9
Ondansetron Approved Phase 4 99614-02-5 4595
10
Remifentanil Approved Phase 4 132875-61-7 60815
11
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
12
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
13
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
14
Nevirapine Approved Phase 4 129618-40-2 4463
15
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
16
Acetaminophen Approved Phase 4 103-90-2 1983
17
Rifapentine Approved, Investigational Phase 4 61379-65-5 6323497
18
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
19
Ibuprofen Approved Phase 4 15687-27-1 3672
20
Cobicistat Approved Phase 4 1004316-88-4
21
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
22
Menthol Approved Phase 4 2216-51-5 16666
23
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
24
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
25
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
26
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
27
Nicotine Approved Phase 4 54-11-5 942 89594
28
Methadone Approved Phase 4 76-99-3 4095
29
Morphine Approved, Investigational Phase 4 57-27-2 5288826
30
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
31
Oxymorphone Approved, Investigational, Vet_approved Phase 4 76-41-5 5284604
32
Trichostatin A Experimental Phase 4 58880-19-6
33
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
34 Respiratory System Agents Phase 4
35 Antitussive Agents Phase 4
36 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
37 Adrenergic alpha-Agonists Phase 4
38 Antihypertensive Agents Phase 4
39 Adrenergic Agents Phase 4
40 Adrenergic Agonists Phase 4
41 Gastrointestinal Agents Phase 4
42 Detox adjuvant Phase 4
43 Sympatholytics Phase 4
44 Hypnotics and Sedatives Phase 4
45 GABA Modulators Phase 4
46 Antipsychotic Agents Phase 4
47 Antiemetics Phase 4
48 Interferon-alpha Phase 4
49 Immunologic Factors Phase 4
50 Interferon alpha-2 Phase 4

Interventional clinical trials:

(show top 50) (show all 660)
# Name Status NCT ID Phase Drugs
1 SPNS Buprenorphine and Integrated HIV Care Evaluation and Support Center: Integration of Buprenorphine and HIV Treatment Using the OASIS Model Unknown status NCT00241930 Phase 4
2 An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Treatment in HIV Primary Care Settings Unknown status NCT00124358 Phase 4 Buprenorphine
3 Integrating Buprenorphine Into the SFGH AIDS Program (Patient Evaluation Study) Completed NCT00263458 Phase 4
4 A Multicenter Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence Completed NCT00007527 Phase 4 naloxone;buprenorphine
5 Feasibility, Mechanism of Action and Potential Side Effects of Extended Release Depot Naltrexone in Opioid Dependent Patients Completed NCT01471145 Phase 4 Naltrexone
6 A Single Center, Randomized, 2 Way Cross-Over, Phase 4 Study Comparing Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 Including Ease of Use, Taste Preference, Dissolution Time, Desire to Abuse, and Overall Acceptance In Buprenorphine/Naloxone Treated Opioid Dependent Population Completed NCT02038790 Phase 4 Suboxone Sublingual Film;Zubsolv sublingual tablets
7 A Phase 4, Pilot, Open-label Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration Completed NCT01453374 Phase 4 VIVITROL 380mg
8 Health Services Research: Extended Release Naltrexone for Opioid-Dependent Youth Completed NCT01843023 Phase 4 Extended Release Naltrexone;Buprenorphine
9 A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Treatment in Opioid Dependent Chronic Back Pain Patients Completed NCT01559454 Phase 4 Methadone;Buprenorphine/naloxone
10 A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4 Methadone;Buprenorphine/naloxone
11 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence Completed NCT00555425 Phase 4
12 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
13 A Feasibility Study for Testing the Effects of Extended-release Naltrexone (Vivitrol) on Recidivism and Other Participant Outcomes in Drug Court Settings Completed NCT02978417 Phase 4 Naltrexone for extended-release injectable suspension;Oral naltrexone
14 Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy Completed NCT01045278 Phase 4 Pegylated interferon-alfa-2b and ribavirin
15 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
16 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
17 Effects of Ketamine On Precipitated Opioid Withdrawal Under General Anaesthesia Completed NCT00300794 Phase 4 Ketamine
18 Counseling for Primary Care Office-based Buprenorphine Completed NCT00595764 Phase 4
19 An Open Multi-center Trial of Suboxone® (Buprenorphine/Naloxone) Treatment Among Opiate-Dependent Subjects Completed NCT00901875 Phase 4 Buprenorphine + naloxone (Suboxone);Buprenorphine + naloxone (Suboxone)
20 Relapse Prevention to Reduce HIV Among Women Prisoners Completed NCT00763958 Phase 4 Placebo;Buprenorphine
21 Buprenorphine/Nx Treatment of Heroin Dependence-A Compassionate Use Study Completed NCT00015340 Phase 4 Buprenorphine/naloxone
22 A Multi-center, Open-Label, 24-Week, Follow-Up Study to Assess Safety, Efficacy, and Treatment Adherence For Maintenance Treatment of Opioid Dependence With OX219 Completed NCT01903005 Phase 4 Higher bioavailability BNX sublingual tablets
23 Evaluation of Preference for a Buprenorphine-based Maintenance Therapy, After a Switch From Buprenorphine Alone (Subutex®) to the Buprenorphine/Naloxone Combination (Suboxone®), in Opioid-dependent Patients With Buprenorphine Maintenance Therapy Completed NCT00684073 Phase 4 buprenorphine;buprenorphine/naloxone
24 An Open-Label Pilot Study of Desvenlafaxine for Opioid-Dependent Patients With Comorbid Depression Completed NCT02200406 Phase 4 Desvenlafaxine
25 Influence of Dexmedetomidine and Lidocaine on Opioid Consumption, Cognitive Function and Incidence of Neuropathic Pain in Laparoscopic Intestine Resection Completed NCT02616523 Phase 4 Dexmedetomidine;Lidocaine;Fentanyl
26 Feasibility Study of Take-Home LAAM Medication Completed NCT00000300 Phase 4 LAAM
27 Neurocognitive Effects of Opiate Agonist Treatment Completed NCT01733693 Phase 4 Buprenorphine;Methadone
28 A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery Completed NCT01374763 Phase 4 Oxycodone;Prolonged-release oxycodone/naloxone
29 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
30 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
31 Administration of Acetazolamide to Prevent Remifentanil Induced Hyperalgesia: Randomize Double Blind Clinical Trial Completed NCT02992938 Phase 4 Acetazolamide;Placebo Oral Tablet
32 Gabapentin Regimens and Their Effects on Opioid Consumption Completed NCT03334903 Phase 4 Gabapentin
33 Naltrexone: Consummatory Behaviors in Alcoholic Women Completed NCT00000448 Phase 4 naltrexone;Placebo
34 A Double-blind Randomised Controlled Clinical Trial of Lofexidine Versus Diazepam in the Management of the Opioid Withdrawal Syndrome During Inpatient Detoxification in Singapore Completed NCT01675648 Phase 4 Lofexidine;Diazepam;Placebo for Lofexidine;Placebo for Diazepam
35 A Multicentre, Randomised, Open-label, Active-controlled Trial of the Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France Completed NCT00955162 Phase 4 Buprenorphine (Subutex);Buprenorphine/naloxone (Suboxone)
36 The Effect of Intraoperative Ketamine on Opioid Consumption and Pain After Spine Surgery in Opioid-dependent Patients Completed NCT02085577 Phase 4 (S)-(+)-Ketamine Hydrochloride Solution 25 mg/ml;Isotonic sodium chloride 0.9 percent;Paracetamol 1 g;Morphine Sulphate 1 mg/ml;Morphine Sulphate 1 mg/ml;Ondansetron 2 mg/ml;Usual daily opioids;Morphine Sulphate 1 mg/ml;Sufentanil 5 microgram/ml
37 A Pharmacokinetic Study to Evaluate the Interaction Between Nevirapine (Viramune®) and Methadone in HIV-1 Infected, Opioid-dependent Adults on Stable Methadone Maintenance Therapy Completed NCT00273988 Phase 4 nevirapine
38 Hydromorphone PCA or Hydromorphone PCA With Ketamine for Acute Postoperative Pain Relief in Opioid-Dependent Chronic Pain Patients Completed NCT01591382 Phase 4 Ketamine;Placebo;Hydromorphone PCA
39 VIVITROL® (Naltrexone for Extended Release Injectable Suspension (XR-NTX)) for Opioid Dependent Inmates Released From Prison Completed NCT01563718 Phase 4 naltrexone for extended release injectable suspension
40 Houston Emergency Opioid Engagement System (HEROES) Recruiting NCT03396276 Phase 4 Suboxone
41 Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings Recruiting NCT03089983 Phase 4 Naltrexone;Methadone;Isoniazid;Rifapentine
42 Buprenorphine Extended-release in Jail and at Re-entry: Open-label Randomized Controlled Trial vs. Daily Sublingual Buprenorphine-naloxone Recruiting NCT03604159 Phase 4 Buprenorphine Extended Release;Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
43 Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Switch Followed by Sofosbuvir/Velpatasvir (SOF/VEL) Antiviral HCV Therapy Followed by Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Simplification in HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy - A Pilot Feasibility Study Recruiting NCT03549312 Phase 4 Genvoya;Epclusa;Biktarvy
44 The Analgesic Efficacy of Continuous Sub-fascial Bupivacaine Infusion and Lidocaine Patches in Post-cesarean Patients With Opiate Use Disorder: A Comparative Efficacy Analysis Recruiting NCT04033562 Phase 4 Lidocaine patch
45 Increasing Access to Hepatitis C Treatment in Opioid Endemic Rural Areas: The Kentucky Viral Hepatitis Treatment (KeY Treat) Study Recruiting NCT03949764 Phase 4 Sofosbuvir/velpatasvir (Epclusa®)
46 Efficacy of Non-Opioid Analgesics in the Management of Pain Following Endoscopic Sinus Surgery: A Multi-Institutional Randomized Controlled Trial Recruiting NCT03783702 Phase 4 OxyCODONE 5 Mg Oral Tablet;Ibuprofen 600 Mg Oral Tablet;Acetaminophen 650 MG Oral Tablet
47 Long Acting Naltrexone for Opioid Addiction: the Importance of Mental, Physical and Societal Factors for Sustained Abstinence and Recovery Recruiting NCT03647774 Phase 4 Extended release naltrexone
48 Use of Oral Pregabalin as Preemptive Analgesia in Abdominal Hysterectomy: Evaluation of Postoperative Pain and Opioid Consumption Recruiting NCT04495374 Phase 4 Pregabalin 300mg
49 Neurocomputational Mechanisms of Mood Improvement Recruiting NCT04276259 Phase 4 Buprenorphine;Naltrexone;Oral Placebo;IM Placebo
50 Bridging Care to HCV Treatment Among Opiate Dependent Patients on Buprenorphine/Naloxone Maintenance Therapy: A Pilot Study of Treating HCV With Epclusa at a Psychiatrist-staffed Outpatient Addiction Clinic Active, not recruiting NCT03235154 Phase 4 sofosbuvir/velpatasvir

Search NIH Clinical Center for Opiate Dependence

Inferred drug relations via UMLS 71 / NDF-RT 51 :


CLONIDINE HCL PWDR
Clonidine Hydrochloride
Levomethadyl
Levomethadyl Acetate Hydrochloride
Methadone
Methadone Hydrochloride
nalmefene
Nalmefene hydrochloride
Naloxone Hydrochloride
Naltrexone
Naltrexone hydrochloride

Genetic Tests for Opiate Dependence

Anatomical Context for Opiate Dependence

MalaCards organs/tissues related to Opiate Dependence:

40
Brain, Amygdala, Bone, Cortex, Breast, Liver, Spinal Cord

Publications for Opiate Dependence

Articles related to Opiate Dependence:

(show top 50) (show all 3541)
# Title Authors PMID Year
1
Functional impact of a single-nucleotide polymorphism in the OPRD1 promoter region. 61 54
20300121 2010
2
Shared mechanisms for opioid tolerance and a transition to chronic pain. 54 61
20357116 2010
3
Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. 61 54
19403243 2009
4
ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. 61 54
18424454 2008
5
Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches? 54 61
18193922 2008
6
The opioid system in alcohol and drug dependence: family-based association study. 54 61
17503481 2007
7
Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis. 61 54
17416470 2007
8
Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments. 54 61
16583408 2006
9
In-vitro and in-vivo characterization of a buprenorphine delivery system. 61 54
16536895 2006
10
A functional prodynorphin promoter polymorphism and opioid dependence. 61 54
16314761 2005
11
Novel exonic mu-opioid receptor gene (OPRM1) polymorphisms not associated with opioid dependence. 54 61
15558714 2005
12
A genetic association study of the mu opioid receptor and severe opioid dependence. 54 61
12960749 2003
13
Introducing a new recruitment approach to sample collection for genetic association studies in opioid dependence. 61 54
12648891 2003
14
D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. 54 61
12497624 2003
15
The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment. 61 54
11054765 2000
16
The DRD2 gene in psychiatric and neurological disorders and its phenotypes. 54 61
11256581 2000
17
Addiction and its reward process through polymorphisms of the D2 dopamine receptor gene: a review. 61 54
10881203 2000
18
Association of alcohol or other drug dependence with alleles of the mu opioid receptor gene (OPRM1). 54 61
9756053 1998
19
Dopamine D3 receptor gene variants and substance abuse in schizophrenia. 54 61
9702743 1998
20
The role of glutamate in physical dependence on opioids. 61 54
9517399 1998
21
Glutamate in opioid dependence. 61 54
9365966 1997
22
Human pharmacology of the opioid neuropeptide dynorphin A(1-13). 54 61
9190848 1997
23
Opioid Dependence After Lung Cancer Resection: Institutional Analysis of State Prescription Drug Database. 61
33221948 2021
24
Anxiety, depression, and opioid misuse among adults with chronic pain: the role of emotion dysregulation. 61
32594288 2021
25
Systematic Evaluation of State Policy Interventions Targeting the US Opioid Epidemic, 2007-2018. 61
33576816 2021
26
Imperfect progress: treatment options for opioid dependence. 61
33539758 2021
27
Preoperative and Postoperative Opioid Dependence in Patients Undergoing Anterior Cervical Diskectomy and Fusion for Degenerative Spinal Disorders. 61
33540452 2021
28
Overview of Tertiary Addictions Services response to Opioid dependence during the COVID-19 Pandemic. 61
33536093 2021
29
Associations between opioid dependence and sweet taste preference. 61
33527169 2021
30
Examining the time-varying association of negative affect and covariates with craving during treatment for prescription opioid dependence with two types of mixed models. 61
33049429 2021
31
Preclinical pharmacokinetic study of speciociliatine, a kratom alkaloid, in rats using an UPLC-MS/MS method. 61
33277117 2021
32
A national database propensity score-matched comparison of minimally invasive and open colectomy for long-term opioid use. 61
33569727 2021
33
Opioid painkiller dependence in a sample of elderly medical inpatients. 61
33594719 2021
34
The Oxford Catalogue of Opioids: a systematic synthesis of opioid drug names and their pharmacology. 61
33608948 2021
35
Naltrexone treatment for prolonged grief disorder: study protocol for a randomized, triple-blinded, placebo-controlled trial. 61
33522931 2021
36
Analgesic opioid use disorders in patients with chronic non-cancer pain: A holistic approach for tailored management. 61
33358994 2021
37
Statistically significant but clinically unimportant: a systematic review and meta-analysis of the analgesic benefits of erector spinae plane block following breast cancer surgery. 61
33168651 2021
38
Automated quantification of opioid withdrawal in neonatal rat pups using Ethovision® XT software. 61
33529734 2021
39
Tobacco use severity in relation to opioid misuse and dependence among adult tobacco users with chronic pain: The moderating role of pain-related anxiety. 61
33545622 2021
40
Multi-environment gene interactions linked to the interplay between polysubstance dependence and suicidality. 61
33431810 2021
41
Social housing promotes recovery of wheel running depressed by inflammatory pain and morphine withdrawal in male rats. 61
32949642 2021
42
Associations between baseline opioid use disorder severity, mental health and biopsychosocial functioning, with clinical responses to computer-assisted therapy treatment. 61
33428458 2021
43
The Psychological Effects of Musculoskeletal Trauma. 61
33475305 2021
44
Functional evaluation of NK1 antagonism on cue reactivity in opiate dependence; An fMRI study. 61
33548897 2021
45
Hospitalisations for non-fatal overdose among people with a history of opioid dependence in New South Wales, Australia, 2001-2018: Findings from the OATS retrospective cohort study. 61
33121866 2021
46
Early life maternal deprivation attenuates morphine induced inhibition in lateral paragigantocellularis neurons in adult rats. 61
33482287 2021
47
Biomarkers to predict staging and treatment response in opioid dependence: A narrative review. 61
33416203 2021
48
Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update. 61
33212514 2021
49
Non-invasive brain stimulation as a tool to decrease chronic pain in current opiate users: A parametric evaluation of two promising cortical targets. 61
33250384 2021
50
A Conantokin Peptide Con-T[M8Q] Inhibits Morphine Dependence with High Potency and Low Side Effects. 61
33478061 2021

Variations for Opiate Dependence

Expression for Opiate Dependence

Search GEO for disease gene expression data for Opiate Dependence.

Pathways for Opiate Dependence

Pathways related to Opiate Dependence according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 VEGFA POMC PDYN OPRM1 OPRK1 OPRD1
2
Show member pathways
13.44 POMC PDYN OPRM1 OPRK1 OPRD1 NPFF
3
Show member pathways
12.61 TH FOS DRD3 DRD2 CREB1
4
Show member pathways
12.51 VEGFA POMC OPRM1 IGF1 FOS CREB1
5 12.42 TPH1 TH POMC OPRM1 NGF CREB1
6 12.16 POMC FOS DRD2 CREB1
8
Show member pathways
11.84 TH PDYN FOS DRD2 CREB1
9 11.78 VEGFA POMC OPRM1 OPRD1 FOS
10
Show member pathways
11.76 TH DRD3 DRD2
11 11.71 POMC FOS CREB1
12 11.66 VEGFA TH NGF IGF1
13 11.64 POMC FOS CREB1
14 11.64 VEGFA TPH1 TH SLC6A4 NGF CREB1
15 11.5 VEGFA FOS CREB1
16 11.41 TH FOS CREB1
17
Show member pathways
11.13 VEGFA POMC FOS
18
Show member pathways
10.82 TH SLC6A4 DRD3 DRD2
19 10.23 TH POMC DRD2 ANKK1

GO Terms for Opiate Dependence

Cellular components related to Opiate Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.83 TH OPRM1 NGF DRD2 CREB1
2 dendrite GO:0030425 9.8 TH PDYN OPRM1 OPRK1 NPFF NGF
3 perikaryon GO:0043204 9.77 TH OPRM1 OPRK1 NPFF DRD2
4 neuron projection GO:0043005 9.7 TPH1 TH SLC6A4 OPRM1 OPRK1 OPRD1
5 integral component of postsynaptic membrane GO:0099055 9.62 SLC6A4 OPRM1 OPRK1 DRD2
6 spine apparatus GO:0097444 9.4 OPRM1 OPRD1
7 axon terminus GO:0043679 9.35 PDYN OPRK1 OPRD1 NPFF DRD2
8 integral component of presynaptic membrane GO:0099056 9.02 SLC6A4 OPRM1 OPRK1 OPRD1 DRD2

Biological processes related to Opiate Dependence according to GeneCards Suite gene sharing:

(show all 49)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.3 VEGFA POMC OPRM1 OPRK1 OPRD1 IGF1
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.2 VEGFA POMC IGF1 FOS DRD3 DRD2
3 G protein-coupled receptor signaling pathway GO:0007186 10.19 POMC PDYN OPRM1 OPRK1 OPRD1 NPFF
4 cytokine-mediated signaling pathway GO:0019221 10.01 VEGFA POMC OPRM1 OPRD1 FOS
5 response to hypoxia GO:0001666 9.92 VEGFA TH SLC6A4 DRD2 CREB1
6 response to toxic substance GO:0009636 9.87 SLC6A4 FOS DRD2
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.87 VEGFA OPRD1 NGF
8 circadian rhythm GO:0007623 9.87 TPH1 SLC6A4 CREB1
9 cellular response to growth factor stimulus GO:0071363 9.85 TH OPRD1 CREB1
10 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.85 OPRM1 OPRK1 OPRD1
11 locomotory behavior GO:0007626 9.85 TH OPRK1 DRD3 DRD2
12 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.84 OPRM1 OPRK1 OPRD1
13 excitatory postsynaptic potential GO:0060079 9.84 OPRM1 NPFF DRD2
14 memory GO:0007613 9.84 TH SLC6A4 NGF CREB1
15 social behavior GO:0035176 9.81 TH SLC6A4 DRD3
16 visual learning GO:0008542 9.8 DRD3 DRD2 CREB1
17 response to nicotine GO:0035094 9.77 TH DRD2 CREB1
18 response to ethanol GO:0045471 9.77 TH OPRM1 OPRK1 DRD3 DRD2
19 response to light stimulus GO:0009416 9.74 TH FOS DRD2
20 response to immobilization stress GO:0035902 9.73 TPH1 TH FOS
21 neurotransmitter biosynthetic process GO:0042136 9.71 TH SLC6A4
22 response to cocaine GO:0042220 9.71 OPRM1 OPRK1 DRD3 DRD2
23 positive regulation of renal sodium excretion GO:0035815 9.7 DRD3 DRD2
24 G protein-coupled receptor internalization GO:0002031 9.7 DRD3 DRD2
25 response to drug GO:0042493 9.7 TH SLC6A4 NPFF FOS DRD3 DRD2
26 prepulse inhibition GO:0060134 9.69 DRD3 DRD2
27 negative regulation of voltage-gated calcium channel activity GO:1901386 9.69 DRD3 DRD2
28 negative regulation of cytosolic calcium ion concentration GO:0051481 9.69 OPRM1 DRD3 DRD2
29 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.68 DRD3 DRD2
30 aromatic amino acid family metabolic process GO:0009072 9.68 TPH1 TH
31 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.68 DRD3 DRD2
32 behavioral response to ethanol GO:0048149 9.67 OPRM1 DRD2
33 behavioral response to cocaine GO:0048148 9.67 OPRK1 DRD3 DRD2
34 hyaloid vascular plexus regression GO:1990384 9.65 TH DRD2
35 acute inflammatory response to antigenic stimulus GO:0002438 9.65 OPRM1 NPFF
36 regulation of potassium ion transport GO:0043266 9.65 DRD3 DRD2
37 sensory perception GO:0007600 9.65 PDYN OPRM1 OPRK1
38 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.63 DRD3 DRD2
39 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.63 DRD3 DRD2
40 synaptic transmission, dopaminergic GO:0001963 9.63 TH DRD3 DRD2
41 response to histamine GO:0034776 9.62 DRD3 DRD2
42 regulation of sensory perception of pain GO:0051930 9.62 OPRM1 OPRK1 OPRD1 NPFF
43 regulation of locomotion involved in locomotory behavior GO:0090325 9.61 DRD3 DRD2
44 opioid receptor signaling pathway GO:0038003 9.61 OPRM1 OPRK1 OPRD1
45 acid secretion GO:0046717 9.6 DRD3 DRD2
46 adenylate cyclase-inhibiting opioid receptor signaling pathway GO:0031635 9.58 OPRM1 OPRK1
47 eating behavior GO:0042755 9.56 TH OPRM1 OPRK1 OPRD1
48 neuropeptide signaling pathway GO:0007218 9.43 POMC PDYN OPRM1 OPRK1 OPRD1 NPFF
49 response to morphine GO:0043278 9.02 OPRM1 OPRK1 NPFF DRD3 DRD2

Molecular functions related to Opiate Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide binding GO:0042277 9.61 OPRM1 OPRK1 OPRD1
2 dopamine binding GO:0035240 9.4 TH DRD2
3 receptor serine/threonine kinase binding GO:0033612 9.37 OPRK1 OPRD1
4 dopamine neurotransmitter receptor activity GO:0004952 9.32 DRD3 DRD2
5 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.26 TPH1 TH
6 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.16 DRD3 DRD2
7 neuropeptide binding GO:0042923 9.13 OPRM1 OPRK1 OPRD1
8 opioid receptor activity GO:0004985 8.8 OPRM1 OPRK1 OPRD1

Sources for Opiate Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....